Results 31 to 40 of about 2,116 (170)

Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis:results from five tralokinumab clinical trials

, 2022
Background: Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin-13, effectively reduces moderate-to-severe atopic dermatitis (AD) when given every 2 weeks.
Boguniewicz, M., Thyssen, J. P., Imafuku, S., Zachariae, R., Wollenberg, A., Beck, L. A., Olsen, C. K., de Bruin Weller, M., Simpson, E. L.   +8 more
core   +1 more source

Targeting interleukin-13 with tralokinumab reduces S. aureus abundance in adolescents with atopic dermatitis

, 2023
International audiencePatients with atopic dermatitis (AD) are frequently colonized with high levels of S.aureus. Dysregulation of the skin microbiome in AD is influenced by epidermal barrier disruption and type 2 inflammation.
Tauber, Marie, Beck, Lisa A., Kurbasic, Azra, Werfel, Thomas, Arlert, Petra, Irvine, Alan, Paller, Amy, Saeki, Hidehisa, Eichenfield, Lawrence, Røpke, Mads, Weidinger, Stephan   +10 more
core   +2 more sources

The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents

, 2023
Atopic dermatitis (AD) is an inflammatory skin disease that frequently occurs in adolescents. Although there are many treatment options, the challenge for clinicians is finding an effective long-term drug for AD with a favorable safety profile.
Adaora R Ewulu, Prajapati, Stuti, Ewulu, Adaora R., Feldman, Steven R., Stuti Prajapati, Steven R Feldman   +5 more
core   +1 more source

Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial* [PDF]

, 2021
© 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists Background: Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key ...
Pink, A. E., Silverberg, J. I., Bang, B., Kurbasic, A., Bieber, T., Weidinger, S., Alexis, A. F., Hijnen, D.; id_orcid, Hijnen, D., Jensen, T. N., Elewski, B. E., Olsen, C. K., Toth, D.   +12 more
core   +2 more sources

The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis

Frontiers in Immunology, 2022
BackgroundSeveral clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD).
Yan Zhang, Yan Zhang, Yan Zhang, Danrong Jing, Danrong Jing, Jun Cheng, Xiang Chen, Xiang Chen, Minxue Shen, Minxue Shen, Hong Liu, Hong Liu   +11 more
doaj   +1 more source

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.

, 2018
BACKGROUND: Tralokinumab is an anti-interleukin-13 human monoclonal antibody developed for the treatment of severe, uncontrolled asthma. These clinical trials aimed to assess the efficacy and safety of tralokinumab in this population.
Peter Wessman (6991784), AnnaMaria Péterffy (7794221), Christopher E. Brightling (7165121), Ulf Sjöbring (2723065), Reynold A. Panettieri (6276716), Gene Colice (5129612), KKarin Bowen (7794224), Edward Piper (7794227)   +7 more
core   +7 more sources

Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations

Journal of Asthma and Allergy
Luca Potestio,1,* Cataldo Patruno,2,* Stefano Dastoli,2 Claudio Brescia,1 Maddalena Napolitano1 1Section of Dermatology Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Department of Health Sciences ...
Potestio L, Patruno C, Dastoli S, Brescia C, Napolitano M   +4 more
doaj   +4 more sources

Tralokinumab for moderate-to-severe atopic dermatitis: A viable option for dupilumab nonresponders [PDF]

JAAD International
Christine T. Olagun-Samuel, BA, Christine C. Akoh, MD, PhD, Nnaemeka Anyanwu, BS, Elizabeth F. Sher, PhD, Carli D. Needle, BA, Jamie Widawsky, PA-C, MPAS, David E. Cohen, MD, MPH, Emily Milam, MD, Alexandra Flamm, MD, Vikash Oza, MD, Theodora K. Karagounis, MD, MS   +10 more
doaj   +2 more sources

Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

, 2022
Background: Additional long-term treatments are needed for moderate-to-severe atopic dermatitis (AD). An ongoing, open-label, 5-year extension trial, ECZTEND (NCT03587805), assesses tralokinumab plus optional topical corticosteroids in participants from ...
Peris K.
core   +1 more source

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis

Pharmaceutics, 2023
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj   +1 more source